High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes

Ahmadzada, Tamkin; Lee, Kenneth; Clarke, C. P.; Cooper, Wendy A.; Linton, A. L.; McCaughan, Brian C.; Asher, Rebecca; Clarke, Stephen; Reid, Glen; Kao, Steven

doi:10.1016/j.lungcan.2019.02.005

Cited by 17 publications

(19 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bin1 loss in a knockout mouse model was associated with elevated STAT1- and NFκB-dependent expression of IDO, driving tumor immune escape ( 21 ). This is supported in vivo by the observation that tumor expression of Bin1 is inversely correlated with IDO expression in esophageal squamous cell cancer and lung cancer ( 16 , 17 ). COX2 has been implicated in the pathogenesis of several cancers, in particular colorectal cancer, where it impacts oncogenic signaling, invasion and metastasis, survival and angiogenesis ( 116 – 118 ).…”

Section: Ido In the Tumor Microenvironmentmentioning

confidence: 74%

IDO Expression in Cancer: Different Compartment, Different Functionality?

2020

View full text Add to dashboard Cite

Indoleamine 2,3-dioxygenase 1 (IDO1) is a cytosolic haem-containing enzyme involved in the degradation of tryptophan to kynurenine. Although initially thought to be solely implicated in the modulation of innate immune responses during infection, subsequent discoveries demonstrated IDO1 as a mechanism of acquired immune tolerance. In cancer, IDO1 expression/activity has been observed in tumor cells as well as in the tumor-surrounding stroma, which is composed of endothelial cells, immune cells, fibroblasts, and mesenchymal cells. IDO1 expression/activity has also been reported in the peripheral blood. This manuscript reviews available data on IDO1 expression, mechanisms of its induction, and its function in cancer for each of these compartments. In-depth study of the biological function of IDO1 according to the expressing (tumor) cell can help to understand if and when IDO1 inhibition can play a role in cancer therapy.

show abstract

Section: Ido In the Tumor Microenvironmentmentioning

confidence: 74%

IDO Expression in Cancer: Different Compartment, Different Functionality?

2020

View full text Add to dashboard Cite

show abstract

“…Then, 299 duplicate publications were excluded, and 153 studies were screened by title and abstract. Subsequently, 119 studies were discarded and 34 studies 9 , 18 – 23 , 27 – 53 were left for eligibility assessment by full-text examination. Eighteen studies were excluded for different reasons: one study did not detect PD-L1 expression in sera samples other than tumor tissues, 37 11 studies did not present sufficient data for meta-analysis, 9 , 38 , 39 , 42 – 48 , 52 two studies did not use unique cut-off value, 40 , 50 one study did not test PD-L1 expression, 41 one study was a letter to the editor, 49 and two studies recruited patients with pleural and peritoneal mesothelioma tumors other than MPM.…”

Section: Resultsmentioning

confidence: 99%

“… 51 , 53 Finally, 16 studies were included in our meta-analysis. 18 – 23 , 27 – 36 The flow chart of the article screening process is shown in Figure 1 .…”

Section: Resultsmentioning

confidence: 99%

“… 18 , 20 – 22 , 27 – 36 All 16 studies 18 – 23 , 27 – 36 provided data on the association between PD-L1 and OS, whereas only two studies reported data on PFS. 19 , 30 With respect to treatment, seven studies enrolled patients receiving surgery, 18 , 27 – 29 , 31 , 35 , 36 three studies recruited patients receiving chemotherapy 19 , 33 or immunotherapy, 30 and six studies included patients receiving mixed treatments (chemotherapy, radiotherapy, and surgery). 20 – 23 , 32 , 34 The detailed information of antibody used in IHC for included studies is shown in Table 2 .…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study

Jin¹,

Xie³

et al. 2020

Ther Adv Med Oncol

View full text Add to dashboard Cite

Background: The prognostic value of programmed death-ligand 1 (PD-L1) expression in patients with malignant pleural mesothelioma (MPM) has been controversial according to previous investigations. Therefore, we conducted a meta-analysis to assess the potential prognostic significance of PD-L1 expression in MPM. Methods: PubMed, Embase, Web of Science, Scopus, and the Cochrane Library were thoroughly searched for relevant original articles published before 9 April 2020. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) of overall survival (OS) and progression-free survival (PFS) were calculated. The results of the meta-analysis were verified using The Cancer Genome Atlas (TCGA) dataset. Results: In total 16 studies were included in our meta-analysis. A high PD-L1 expression was associated with a poor OS (HR = 1.53, 95% CI = 1.28–1.83, p < 0.001), but not a grave PFS (HR = 1.07, 95% CI = 0.82–1.39, p = 0.643) in MPM. Furthermore, the PD-L1 expression correlated with the sarcomatoid + biphasic type of MPM (odds ratio = 4.32, 95% CI = 2.16–8.64, p < 0.001). TCGA data indicated that PD-L1 was a significant prognostic factor for OS (HR = 2.069, 95% CI = 1.136–3.769, p = 0.0175), but not for PFS (HR = 1.205, 95% CI = 0.572–2.539, p = 0.624), which was in accordance with the results of the meta-analysis. Conclusion: A high PD-L1 expression is a significant prognostic factor for poor OS of patients with MPM. We therefore suggest that PD-L1 expression levels can be used to predict the clinical outcomes of patients with MPM in the future.

show abstract

“…In the included studies, a total of 28 studies analyzed the association between IDO expression and OS. Of these 28 studies, 3 studies with HR < 1 [38,39,41], and 18 studies with HR > 2 [14-16, 18-22, 24, 27, 29, 30, 33, 34, 37, 42-44]. We performed a meta-analysis of 28 studies.…”

Section: Impact Of Ido Expression On Cancer Prognosismentioning

confidence: 99%

The prognostic value of IDO expression in solid tumors: a systematic review and meta-analysis

Wang

Shen

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

Background: Indoleamine 2,3-dioxygenase (IDO) is a rate-limiting enzyme in the metabolism of tryptophan into kynurenine. It is considered to be an immunosuppressive molecule that plays an important role in the development of tumors. However, the association between IDO and solid tumor prognosis remains unclear. Herein, we retrieved relevant published literature and analyzed the association between IDO expression and prognosis in solid tumors. Methods: Studies related to IDO expression and tumor prognosis were retrieved using PMC, EMbase and web of science database. Overall survival (OS), time to tumor progression (TTP) and other data in each study were extracted. Hazard ratio (HR) was used for analysis and calculation, while heterogeneity and publication bias between studies were also analyzed. Results: A total of 31 studies were included in this meta-analysis. Overall, high expression of IDO was significantly associated with poor OS (HR 1.92, 95% CI 1.52-2.43, P < 0.001) and TTP (HR 2.25 95% CI 1.58-3.22, P < 0.001). However, there was significant heterogeneity between studies on OS (I 2 = 81.1%, P < 0.001) and TTP (I 2 = 54.8%, P = 0.007). Subgroup analysis showed lower heterogeneity among prospective studies, studies of the same tumor type, and studies with follow-up periods longer than 45 months. Conclusions: The high expression of IDO was significantly associated with the poor prognosis of solid tumors, suggesting that it can be used as a biomarker for tumor prognosis and as a potential target for tumor therapy.

show abstract

High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes

Cited by 17 publications

References 56 publications

IDO Expression in Cancer: Different Compartment, Different Functionality?

IDO Expression in Cancer: Different Compartment, Different Functionality?

PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study

The prognostic value of IDO expression in solid tumors: a systematic review and meta-analysis

Contact Info

Product

Resources

About